Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novametrix Medical Systems, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Roland Batson who wrote (183)	7/2/1999 11:00:00 AM
From: Elvis Jones	Respond to of 207

Quick random thoughts... NMTX needs to show better earnings. They have disappointed 'the street' enough that Zacks shows no analysts covering the company. Stabilizing earnings helps, but momentum must come. This means NMTX is a 'forgotten' company, which can only benefit by showing results. NMTX needs to lower the ratio of SG&A to Sales. I believe this is where your concerns hit the bottom line. The purchase of ChMV will add 27% to revenues (comparing 9mil projected for ChMV to NMTX's FY99 of 33mil). Can the company find some economies-of-scale in this to reduce SG&A? It can only help. Good Luck! Happily Following NMTX, Duke